Aquestive’s Anaphylm could become the first oral epinephrine for severe allergic reactions after the FDA set a 2026 decision date without panel review.
Latest Ratings for AQST
DateFirmActionFromTo Sep 2020RBC CapitalMaintainsOutperform Sep 2020HC Wainwright & Co.MaintainsBuy May 2020HC Wainwright & Co.MaintainsBuy